High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19
Open Access
- 25 July 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (12), 2150-2160
- https://doi.org/10.1093/infdis/jiac313
Abstract
Immune dysregulation is a major factor in the development of severe coronavirus disease 2019 (COVID-19). The homeostatic chemokines CCL19 and CCL21 have been implicated as mediators of tissue inflammation, but data on their regulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is limited. We thus investigated the levels of these chemokines in COVID-19 patients. Serial blood samples were obtained from patients hospitalized with COVID-19 (n = 414). Circulating CCL19 and CCL21 levels during hospitalization and 3-month follow-up were analyzed. In vitro assays and analysis of RNAseq data from public repositories were performed to further explore possible regulatory mechanisms. A consistent increase in circulating levels of CCL19 and CCL21 was observed, with high levels correlating with disease severity measures, including respiratory failure, need for intensive care, and 60-day all-cause mortality. High levels of CCL21 at admission were associated with persisting impairment of pulmonary function at the 3-month follow-up. Our findings highlight CCL19 and CCL21 as markers of immune dysregulation in COVID-19. This may reflect aberrant regulation triggered by tissue inflammation, as observed in other chronic inflammatory and autoimmune conditions. Determination of the source and regulation of these chemokines and their effects on lung tissue is warranted to further clarify their role in COVID-19. NCT04321616 and NCT04381819.Keywords
Funding Information
- National Program of Clinical Therapy Research in the Specialist Health Services, Norway (2020201)
- Oslo University Hospital
- Research Council of Norway (312780)
- Vivaldi Invest A/S
- South-Eastern Norway Regional Health Authority (2021071)
- European Union (71029)
This publication has 47 references indexed in Scilit:
- CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic SclerosisArthritis & Rheumatology, 2018
- Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx componentsPLoS Pathogens, 2017
- Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cellsCardiovascular Research, 2014
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivoBlood, 2013
- Characterization of CCL19 and CCL21 in rheumatoid arthritisArthritis & Rheumatism, 2011
- Jak3 Is Involved in Dendritic Cell Maturation and CCR7-Dependent MigrationPLOS ONE, 2009
- CCR 7 Ligands Are Required for Development of Experimental Autoimmune Encephalomyelitis through Generating IL-23-Dependent Th17 CellsThe Journal of Immunology, 2009
- Enhanced Expression of the Homeostatic Chemokines CCL19 and CCL21 in Clinical and Experimental AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Selectin Ligand-Independent Priming and Maintenance of T Cell Immunity during Airborne TuberculosisThe Journal of Immunology, 2006
- The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunityImmunological Reviews, 2003